The aim is to find out whether a shorter course of the antifungal medication works as well as the usual 14‑day regimen after the infection has cleared, meaning it is not worse (non‑inferior). Participants receive the assigned IV medication for a limited period and then continue to be observed for about a month.

During the follow‑up period, doctors check for any return of the infection, overall health status, and any side effects from the drug. Simple questionnaires are used to capture quality of life and physical functioning, and routine tests are performed to confirm that the fungus has been eliminated.

The purpose of the study is to find out if treating uncomplicated candidemia, which means the infection has not spread to other parts of the body, for 7 days after the first blood test shows no more yeast is as effective as treating it for 14 days after that first clear blood test. The study will compare how many patients are alive 28 days after their first negative blood culture between the two treatment durations. Patients in the study will receive one of the antifungal medications mentioned above, and the length of treatment will depend on which group they are randomly assigned to.

During the study, patients will have blood tests to check their liver function and to confirm that the infection has cleared. The study will also track whether the infection comes back or spreads to other parts of the body. Patients will be followed for up to 45 days to monitor their recovery and check for any signs that the infection has returned. The study will also look at the costs associated with each treatment duration to understand the economic impact of the different approaches.

The purpose of this study is to evaluate how Rezafungin behaves in the body of patients who are receiving ECMO, with or without RRT. This includes understanding how the drug is absorbed, distributed, and eliminated from the body. The study will monitor the levels of Rezafungin in the blood to gather this information. Patients participating in the study will receive Rezafungin as part of their treatment for invasive candidiasis, and their response to the medication will be closely observed.

Throughout the study, researchers will also look at how different factors, such as additional medical treatments, body weight, and gender, might affect the levels of Rezafungin in the blood. Additionally, any side effects experienced by patients will be recorded, as well as any reasons for stopping the treatment. The study aims to provide valuable insights into the use of Rezafungin in critically ill patients, helping to improve treatment strategies for those with invasive candidiasis.

The purpose of the study is to evaluate how well the new treatment works in adults with these infections. Participants will receive either the new treatment or the standard treatment, and some may receive a placebo. The study will monitor participants over a period to see how their infections respond to the treatments. This includes checking for improvements in symptoms and any side effects that may occur. The study aims to provide valuable information on whether the new treatment is a better option for managing these infections.

Participants will be closely monitored by healthcare professionals throughout the study. The study will involve regular check-ups and tests to track the progress of the treatment and ensure the safety of all participants. The results of this study could help improve treatment options for people suffering from these serious fungal infections in the future.

The purpose of this research is to determine if adding rIFN-gamma 1b to the standard treatment helps clear the Candida infection from the blood more effectively. During the study, participants receive either the study medication along with standard therapy or standard therapy alone. The treatment period lasts up to 2 months, with the medication being administered under the skin at a dose of up to 50 micrograms per square meter of body surface.

Throughout the study, doctors monitor how quickly the infection clears from the blood and track the overall health status of participants. They also observe how well patients tolerate the treatment and any changes in their condition. Blood samples are collected to measure various health indicators and to study how the treatment affects the body’s immune response to the infection.

The purpose of the study is to determine if the treatment with intravenous echinocandin followed by oral Ibrexafungerp is as effective as the treatment with intravenous echinocandin followed by oral Fluconazole. Participants in the study will receive one of these treatment regimens. The study will last for a period of up to six months, during which participants will be monitored for their response to the treatment and any side effects they may experience.

Throughout the study, participants will receive regular check-ups to assess their health and the effectiveness of the treatment. The study will help researchers understand which treatment regimen is more effective in treating Invasive Candidiasis and Candidemia, potentially leading to better treatment options for patients in the future.